Helsinn Healthcare SA, a Switzerland-based pharma company, today said it has entered into a settlement agreement with Dr Reddy's Laboratories to resolve certain patent litigations relating to the former's drug Aloxi (palonosetron HCl injection) in the United States.
Aloxi injection is used in adults to help prevent the nausea and vomiting due to chemotherapy.
According to a statement issued by the Swiss drug maker, Aloxi is currently distributed by Helsinn Healthcare's marketing partner, Eisai Inc in the USA.
"As a result of the settlement, Dr Reddy's Laboratories Inc will be permitted to market a 505(j) generic version of Aloxi in the United States on September 30, 2018 or earlier under certain circumstances. The terms of the settlement agreement are otherwise confidential," the statement said.
Dr Reddy's and Helsinn are engaged in a legal battle on the patent related issues over Aloxi.
Helsinn had earlier entered into similar agreement with Sandoz Inc.
Shares of Dr Reddy's were trading at Rs 4,178.40 apiece, down 0.29 per cent on BSE.
